SLAS2017 Short Courses

Pharmacology in Drug Discovery and Development: New Lives for Receptors as Drug Targets Through Allostery and Biased Signaling NEW!

This course discusses new ideas about efficacy (efficacy fingerprints, biased signaling) and allosteric receptor function to improve definition and quantification of GPCR drug activity, better target drug activity (i.e. pathway vs target validation) and predict therapeutic activity profiles. Specifically, methods to guide SAR for biased signaling and allosteric ligand activity will be featured.

Who Should Attend:

How You Will Benefit From This Course:

Course Topics:


Terry Kenakin
UNC School of Medicine, Chapel Hill, NC

After obtaining a BSc in chemistry and Ph.D. in Pharmacology at the University of Alberta, Dr. Kenakin worked for 3 years at University College London UK with Prof. Sir James Black. From there he spent 32 years in industry (7 Burroughs-Wellcome ,25 GlaxoSmithKline). He currently is Professor at the University of North Carolina School of Medicine. His interests have always been in quantitative pharmacodynamics and the discovery of new drugs and he has worked on projects for AIDs, heart failure and metabolic diseases. He is editor and chief of Journal of Receptors and Signal Transduction, and co-Editor in Chief of Current Opinion in Pharmacology. He has written 10 books on pharmacology.